You should contact your healthcare provider promptly if you experience any of the following: Severe or worsening abdominal pain Bloating that does not improve after 2-3 weeks Significant distress or interference with daily activities Signs of dehydration, such as dizziness, dark urine, or reduced urination Signs of a possible allergic reaction (rash, swelling of face/throat, difficulty breathing) Bloating accompanied by persistent vomiting or inability to keep fluids down Long-term outlook The majority of patients find that bloating eases within 48 weeks as their bodies get used to the medication
Large-scale clinical trials have demonstrated that GLP-1RAs predominantly exhibit neutral or suppressive effects on overall cancer risk, with semaglutide showing no elevated cancer incidence [14], while significant reductions have been observed in specific malignancies, particularly liver cancers and prostate cancers [13, 15]
You have a powerful blend that theoretically covers all the bases: Inflammation Control (KPV): Creates a stable environment for healing
As of December 2024, the FDA approved tirzepatide for treatment of moderate-to-severe obstructive sleep apnea (OSA) in patients with obesity based on the results of two trials
Exercise also benefits pelvic floor function and blood flow, providing indirect protection against UTIs